Key result
Antenatal exposure to sartans during the last two trimesters of pregnancy was associated with severe adverse fetal outcomes, including fetal renal failure, anamnios, and hypocalvaria in two cases.
Why the study?
Does antenatal exposure to sartans cause adverse fetal outcomes in hypertensive pregnancies?
Case Report (n=2)
Does antenatal exposure to sartans cause adverse fetal outcomes in hypertensive pregnancies?
The use of sartans during the last two trimesters of pregnancy is associated with severe adverse fetal outcomes, including renal failure and hypocalvaria, and should be strictly avoided.
Sartan exposure linked to fetal renal failure and anomalies warrants avoidance in pregnancy; leaves open systematic risk quantification in larger studies.
Sartans are selective type 1 angiotensin II receptor-antagonists that are used in the treatment of arterial hypertension. Few reports are available concerning the use of sartans during pregnancy. We report two cases of adverse fetal outcome in hypertensive pregnancies exposed to sartans. In the first case, anamnios and fetal renal failure due to severe tubular dysgenesia led to termination of pregnancy in the 27th week. The second patient presented with hypocalvaria and developed fetal renal failure. The use of sartans during the two last trimesters of pregnancy should be strictly avoided.
No takes yet. Share an insight, caveat, or question.
Vendemmia et al. (2005) conducted a case report in Hypertensive pregnancies (n=2). Sartans (type 1 angiotensin II receptor-antagonists) was evaluated on Adverse fetal outcome (fetal renal failure, anamnios, hypocalvaria). Antenatal exposure to sartans during the last two trimesters of pregnancy was associated with severe adverse fetal outcomes, including fetal renal failure, anamnios, and hypocalvaria in two cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: